A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV)
Innovations in Surgery and Interventional Medicine · 2021
DOI: 10.36401/isim-20-03 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innovations in Surgery and Interventional Medicine, 2021. Verfasst von D'Andrea K. Joseph und 7 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Pneumonia leading to acute respiratory distress syndrome (ARDS) is one of the devastating consequences of coronavirus disease 2019 (COVID-19). Airway pressure release ventilation (APRV) has been described as beneficial in acute lung injury and ARDS. We hypothesized that utilizing APRV would be advantageous in the COVID-19 ARDS population.
Methods
Prospective, observational, single-center study. Data were extracted on demographics, vasopressors, sedatives, analgesics, and oxygenation (PaO2/FiO2). A generalized linear mixed models analysis was performed to compare low tidal volume ventilation (LTV) with APRV for patients who required intubation due to ARDS from COVID-19 and who were managed with at least 48 consecutive hours of APRV in our surgical intensive care unit (SICU).
Results
Twelve patients met criteria; two were on APRV mode from admission to the SICU and were not included in the study. Ten patients were analyzed and were primarily male (70%), average age of 64.5 ± 12.9 years, and 70% were obese (average body mass index of 30.6 ± 8.0 kg/m2). There were no smokers in the sample, but two patients presented with underlying lung pathology. APRV was shown to significantly increase the PaO2/FiO2 ratio by 30% (5% to 61%) (p = 0.05) and was associated with up to a 12% (−26% to 5%) reduction in the level of FiO2 and reduction in the use of vasopressor support (−59% [−83% to −2%]), sedatives (−15% [−29% to 2%]), and analgesics (−16% [−38% to 12%]).
Conclusions
This pilot study showed that APRV was associated with decreases in FiO2, vasopressors, sedatives, and analgesic requirements with an increase in PaO2/FiO2 ratio. In the current pandemic, where providers are grappling with ways to manage COVID-19 ARDS, APRV may be the optimal ventilator mode. Prospective randomized studies are required to validate whether use of APRV in the COVID-19 population leads to improved oxygenation and a subsequent decrease of ventilator days and length of stay.
Zitieren
APA
Joseph, D. K., Baltazar, G. A., Jacquez, R. A., Islam, S., Stright, A., Divers, J., Brathwaite, C. E., & Petrone, P. (2021). A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV). Innovations in Surgery and Interventional Medicine. https://doi.org/10.36401/isim-20-03
Vancouver
Joseph DK, Baltazar GA, Jacquez RA, Islam S, Stright A, Divers J, et al. A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV). Innovations in Surgery and Interventional Medicine. 2021. doi:10.36401/isim-20-03
BibTeX
@article{Joseph2021,
author = {Joseph, D'Andrea K. and Baltazar, Gerard A. and Jacquez, Ricardo A. and Islam, Shahidul and Stright, Adam and Divers, Jasmin and Brathwaite, Collin E.M. and Petrone, Patrizio},
title = {A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV)},
journal = {Innovations in Surgery and Interventional Medicine},
year = {2021},
doi = {10.36401/isim-20-03}
}
EUVIMED